
Rome Therapeutics, a biotechnology company, has closed $77 million in Series B financing. Section 32 led the round with participation from other backers that included Sanofi Ventures, Casdin Capital, Andreessen Horowitz and Alexandria Venture Investments.
Source: Press Release